Press Releases

Aug 05, 2022

MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS

Jul 29, 2022

Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

Jul 07, 2022

Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction

Jul 07, 2022

Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter

Jun 20, 2022

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

May 26, 2022

Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

May 23, 2022

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

May 17, 2022

Meridian Bioscience Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

May 06, 2022

MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS

May 02, 2022

Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities

Apr 07, 2022

Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter

Mar 29, 2022

Meridian Bioscience Launches Lyo-Ready™ qPCR Inhibitor Tolerant Blood-Specific Master Mixes for DNA & RNA Direct Detection

Feb 21, 2022

Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer

Feb 16, 2022

Magellan Diagnostics Resumes Distribution of LeadCare® II Test Kits

Feb 04, 2022

MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY

Jan 31, 2022

Meridian Bioscience Receives Additional NIH Award to Support the Rapid Development of the Revogene® Molecular Viral Respiratory Testing Panel

Jan 28, 2022

Meridian Bioscience Launches Lyo-Ready™ qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Jan 27, 2022

Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board

Jan 10, 2022

Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference Call on February 4, 2022

Jan 05, 2022

Meridian Bioscience Receives FDA-Clearance for the Curian® Campy Assay

Innerpage

MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS

Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction

Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

Meridian Bioscience Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS

Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities

Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter

Meridian Bioscience Launches Lyo-Ready™ qPCR Inhibitor Tolerant Blood-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer

Magellan Diagnostics Resumes Distribution of LeadCare® II Test Kits

MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY

Meridian Bioscience Receives Additional NIH Award to Support the Rapid Development of the Revogene® Molecular Viral Respiratory Testing Panel

Meridian Bioscience Launches Lyo-Ready™ qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board

Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference Call on February 4, 2022

Meridian Bioscience Receives FDA-Clearance for the Curian® Campy Assay